Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
The company has responded to the warning letter and carried out the committed corrections.
Strides is the first Indian company to get approval for the product.
he US FDA has issued six observations pursuant to the completion of the audit.
He was appointed a Board member and the Chairman in 2012.
The company has reported total income of Rs. 128.79 crores during the period ended June 30, 2022.
The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
Subscribe To Our Newsletter & Stay Updated